The estimated Net Worth of Dan Lemaitre is at least $8.25 million dollars as of 15 May 2023. Mr. Lemaitre owns over 43,450 units of Globus Medical Inc stock worth over $3,757,898 and over the last 15 years he sold GMED stock worth over $4,092,585. In addition, he makes $404,459 as Independent Director at Globus Medical Inc.
Daniel has made over 8 trades of the Globus Medical Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he sold 63,300 units of GMED stock worth $4,089,813 on 10 May 2024.
The largest trade he's ever made was selling 63,300 units of Globus Medical Inc stock on 10 May 2024 worth over $4,089,813. On average, Daniel trades about 5,821 units every 71 days since 2009. As of 15 May 2023 he still owns at least 54,250 units of Globus Medical Inc stock.
You can see the complete history of Mr. Lemaitre stock trades at the bottom of the page.
Daniel T. Lemaitre serves as Independent Director of the Company. Mr. Lemaitre most recently served as the President and Chief Executive Officer of Direct Flow Medical. Previously, Mr. Lemaitre served as Chief Executive Officer of White Pine Medical, a venture-backed medical device start-up company, from June 2009 until May 2015. Prior to White Pine Medical, Mr. Lemaitre served as the President and Chief Executive Officer of CoreValve, a privately-held company focused on percutaneous aortic valve replacement, from April 2008 until its acquisition by Medtronic, Inc., a publicly-traded medical device company, in April 2009. From 2005 until March 2008, Mr. Lemaitre was a Senior Vice President at Medtronic, where he led the company’s strategic planning and corporate development. Prior to joining Medtronic, Mr. Lemaitre spent 28 years as an investment analyst in the medical device field. This included 18 years with SG Cowen, where he was a managing director and led the healthcare research team, and six years with Merrill Lynch. Mr. Lemaitre holds a B.A. in Economics from Bethany College and an M.B.A. from Bowling Green State University. Mr. Lemaitre also currently serves as the Chairman of the Board of Directors of Endologix, Inc. (NASDAQ: ELGX). Mr. Lemaitre’s extensive business, managerial, executive and leadership experience in the medical device industry, including having served as chief executive officer of a medical device company and as senior vice president of one of the world’s leading medical technology companies, as well as his current experience as a director of a publicly-traded medical device company bring to our Board of Directors a meaningful understanding of our business and industry and valuable skills related to strategic planning for a public company. These skills and experience, as well as his financial and accounting skills and expertise, qualify him to serve as one of our directors and as an “audit committee financial expert” on our Audit Committee.
As the Independent Director of Globus Medical Inc, the total compensation of Daniel Lemaitre at Globus Medical Inc is $404,459. There are 13 executives at Globus Medical Inc getting paid more, with David Demski having the highest compensation of $3,449,790.
Daniel Lemaitre is 66, he's been the Independent Director of Globus Medical Inc since 2011. There are 1 older and 17 younger executives at Globus Medical Inc. The oldest executive at Globus Medical Inc is James Tobin, 75, who is the Independent Director.
Dan's mailing address filed with the SEC is VALLEY FORGE BUSINESS CENTER, 2560 GENERAL ARMISTEAD AVENUE, AUDUBON, PA, 19403.
Over the last 12 years, insiders at Globus Medical Inc have traded over $375,265,297 worth of Globus Medical Inc stock and bought 2,005 units worth $99,824 . The most active insiders traders include David C Paul, Kurt Wheeler et David M Demski. On average, Globus Medical Inc executives and independent directors trade stock every 42 days with the average trade being worth of $11,005,133. The most recent stock trade was executed by Leslie V Norwalk on 11 July 2024, trading 1,000 units of GMED stock currently worth $70,000.
globus medical, inc. is a leading musculoskeletal implant manufacturer and is driving significant technological advancements across a complete suite of spinal products. founded in 2003, globus’ single-minded focus on advancing spinal surgery has made it the fastest growing company in the history of orthopedics. globus is driven to utilize superior engineering and technology to achieve pain free, active lives for all patients with spinal disorders. additional information can be accessed at www.globusmedical.com.
Globus Medical Inc executives and other stock owners filed with the SEC include: